Overview

The WHO recommends that **trivalent** vaccines for use in the 2025-2026 northern hemisphere influenza season contain the following:

Egg-based vaccines

- an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
- an A/Croatia/10136RV/2023 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture-, recombinant protein- or nucleic acid-based vaccines

- an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
- an A/District of Columbia/27/2023 (H3N2)-like virus; and
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations:

- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

引用元：WHO ウェブサイト

Recommended composition of influenza virus vaccines for use in the 2025-2026 northern hemisphere influenza season

World Health Organization

Influenza A(H1N1)pdm09 egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2025-2026 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

28 February 2025

Candidate vaccine viruses (CVVs) antigenically like A/Victoria/4897/2022 (egg-derived) - Accession number (GISAID): EPI_ISL_16714268

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Victoria/4897/2022	Wild type virus			WHO CCs MHRA, UK
	IVR-238	Classical	Seqirus	CCDC, China MHRA, UK VIDRL, Australia NIID, Japan
A/West Virginia/30/2022	Wild type virus			CDC, USA MHRA, UK
	IVR-239	Classical	Seqirus	VIDRL, Australia NIID, Japan
	X-393	Classical	NYMC	NYMC, USA MHRA, UK
	X-393A	Classical	NYMC	MHRA, UK NYMC, USA
A/Wisconsin/67/2022	Wild type virus			CDC, USA MHRA, UK
	X-397	Classical	NYMC	CDC, USA
A/Norway/31694/2022	Wild type virus			FCI, UK MHRA, UK
	NIB-133	Classical	MHRA	MHRA, UK
A/Catalonia/NSVH161512065/2022	Wild type virus			FCI, UK
	NIB-134	Classical	MHRA	MHRA, UK
A/Sichuan-Qingyang/SWL1148/2023	Wild type virus			WHO CCs
	CNIC-2301	Classical	CNIC	CCDC, China CBER/FDA, USA MHRA, UK,

引用元：WHO ウェブサイト
https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses

World Health Organization

Influenza A(H3N2) egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2025-2026 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two- way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

28 February 2025

Candidate vaccine viruses antigenically like A/Croatia/10136RV/2023 (egg-derived) - Accession number (GISAID): EPI_ISL_19085873

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Croatia/10136RV/2023	Wild type		FCI	MHRA, UK
	NIB-146	Classical	MHRA	
	X-425A		NYMC	MHRA, UK CCDC, China
	IVR-263		Seqirus	VIDRL, Australia
A/District of Columbia/27/2023	Wild type		CDC	CDC, USA
	NIB-142	Classical	MHRA	MHRA, UK
				NIID, Japan
	SAN-037		Sanofi	MHRA, UK pending
A/Perth/722/2024	Wild type		VIDRL	VIDRL, Australia
	IVR-262	Classical	Seqirus	
				NIID, Japan

引用元：WHO ウェブサイト
https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses

World Health Organization

Influenza B Victoria lineage egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2025-2026 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

28 February 2025 (*Last updated 28 March 2025*)

Candidate vaccine viruses (antigenically like B/Austria/1359417/2021 (egg derived) - Accession number (GISAID): EPI_ISL_1519459

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Austria/1359417/2021	Wild type virus			WHO CCs MHRA, UK
B/Austria/1359417/2021	BVR-26	Classical	Seqirus	VIDRL, Australia MHRA, UK NIID, Japan
B/Austria/1359417/2021	BX-107A	Classical	NYMC	CDC, USA MHRA, UK NYMC, USA
B/Michigan/01/2021	Wild type virus			CDC, USA MHRA, UK NIID, Japan
B/Singapore/WUH4618/2021	Wild type virus			WHO CCs MHRA, UK
B/Guangdong-Zhenjiang/1516/2021	Wild type virus			WHO CCs MHRA, UK
B/Guangdong-Zhenjiang/1516/2021	CNIC-2107A	Classical	CCDC, China	WHO CCs
B/Zhejiang-Nanhu/1854/2021	Wild type virus			WHO CCs
B/Zhejiang-Nanhu/1854/2021	BX-117	Classical	NYMC	NYMC, USA
B/Zhejiang-Xiacheng/11085/2021	Wild type virus			WHO CCs
B/Zhejiang-Xiacheng/11085/2021	BX-115	Classical	NYMC	NYMC, USA
B/Shaanxi-Baota/1278/2022	Wild type virus			WHO CCs
B/Shaanxi-Baota/1278/2022	BX-121	Classical	NYMC	NYMC, USA
B/Shaanxi-Baota/1278/2022	BX-121A	Classical		

引用元：WHO ウェブサイト
https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses

World Health Organization

Influenza B Yamagata lineage egg-derived[1] candidate vaccine viruses for development and production of vaccines for use in the 2025-2026 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or Regional control authorities approve the composition and formulation of vaccines used in each country[2]

28 February 2025

Candidate vaccine viruses (antigenically like B/Phuket/3073/2013 (egg derived) - Accession number (GISAID): EPI_ISL_168822

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Phuket/3073/2013	Wild type virus			WHO CCs MHRA, UK*
	BVR-1B	Classical	Seqirus	VIDRL, Australia
B/California/12/2015	Wild type virus			CDC, USA
	BX-59A	Classical	NYMC	MHRA, UK* NYMC, USA
	BX-59B			MHRA, UK* NYMC, USA
B/Brisbane/9/2014	Wild type virus			WHO CCs MHRA, UK*
B/Utah/09/2014	Wild type virus			CDC, USA MHRA, UK*
B/Arizona/10/2015	BX-63	Classical	NYMC	MHRA, UK* NYMC, USA
	BX-63A			MHRA, UK* NYMC, USA
B/Hong Kong/3417/2014	Wild type virus			NYMC, USA MHRA, UK*
	BX-57	Classical	NYMC	MHRA, UK* NYMC, USA

**B/Yamagata viruses are available for manufacture of quadrivalent vaccines by request (standards@mhra.gov.uk)*

引用元：WHO ウェブサイト
https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses